On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Annovis Bio Inc. (NYSE American: ANVS) Starts Presentation at The LD 500

Annovis Bio Inc. (NYSE American: ANVS) is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease, Parkinson’s disease and Alzheimer’s in Down Syndrome. With an aging population, neurodegenerative diseases have become one of the world’s largest unmet medical needs. Nerve cell death is the underlying cause of all neurodegenerative disease in both slow chronic and fast acute injuries to the brain. Annovis is developing novel treatments that are expected to improve memory loss and dementia associated with Alzheimer’s disease and Alzheimer’s in Down Syndrome, as well as body and brain function in Parkinson’s disease. Annovis has an ongoing Phase 2a study in Alzheimer’s disease patients and plans to begin a second Phase 2a study in Parkinson’s disease and Alzheimer’s disease patients. For more information, visit the company’s website at www.annovisbio.com

About The LD 500

The LD 500 is the most ambitious project in LD Micro’s 14-year history of leading the micro-cap space as an independent resource. Investors will enjoy updates from hundreds of companies that represent a wide variety of industries. Featuring some of the most prominent companies in the micro-cap world, the LD 500 also incorporates interviews and keynotes with small-cap royalty.

To view InvestorBrandNetwork’s virtual coverage, which includes one-click access to market research tools on the presenting companies, visit: http://ibn.fm/TheLD500

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Archives

Select A Month

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217